Prevalence of refractoriness when testing growth hormone levels in children.


Journal

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
ISSN: 1532-2238
Titre abrégé: Growth Horm IGF Res
Pays: Scotland
ID NLM: 9814320

Informations de publication

Date de publication:
08 2023
Historique:
received: 25 04 2023
revised: 19 07 2023
accepted: 22 07 2023
medline: 31 8 2023
pubmed: 11 8 2023
entrez: 10 8 2023
Statut: ppublish

Résumé

Late night spontaneous growth hormone (GH) pulses may influence the pituitary GH response to provocation tests. We evaluated GH response during arginine-insulin-tolerance test (AITT) after a GH peak during a short spontaneous nocturnal profile (SSNP) in children with short stature or low growth velocity. Using SSNP and subsequent AITT, we examined 257 children 4-18 years old (138 (53.7%) males) recruited from three hospitals. Medical records were reviewed retrospectively. Refractory children were defined as a GH peak ≥7 μg/L during SSNP but no GH peak ≥7 μg/L during AITT. In total, 201/257 children had a GH peak ≥7 μg/L at SSNP and/or AITT. Of these, 21.9% were refractory. The proportion of males (p = 0.033) and body mass index (BMI) standard deviation score (SDS) (p = 0.037) were higher in the refractory group than in children with a GH peak ≥7 μg/L during AITT. The median period between last GH peak ≥7 μg/L during SSNP and GH Many children with short stature were refractory at testing; among them we found few clinical characteristics. Refractoriness might be influenced by some differences in procedure, but needs to be considered when evaluating GH response in children.

Identifiants

pubmed: 37562165
pii: S1096-6374(23)00027-8
doi: 10.1016/j.ghir.2023.101549
pii:
doi:

Substances chimiques

Insulin-Like Growth Factor I 67763-96-6
Growth Hormone 9002-72-6
Human Growth Hormone 12629-01-5
Insulin 0
Arginine 94ZLA3W45F

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101549

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no competing interests to declare.

Auteurs

Camilla Borghammar (C)

Lund University, Skåne University Hospital, Department of Clinical Sciences, Pediatrics, Pediatric Endocrinology, Lund, Sweden. Electronic address: camilla.borghammar@med.lu.se.

Victoria Boije (V)

Lund University, Skåne University Hospital, Department of Clinical Sciences, Pediatrics, Pediatric Endocrinology, Lund, Sweden.

Charlotte Becker (C)

Department of Clinical Chemistry and Pharmacology, University and Regional Laboratories, Region Skåne, Sweden.

Bengt Lindberg (B)

Lund University, Skåne University Hospital, Department of Clinical Sciences, Pediatrics, Pediatric Endocrinology, Lund, Sweden.

Maria Elfving (M)

Lund University, Skåne University Hospital, Department of Clinical Sciences, Pediatrics, Pediatric Endocrinology, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH